Growth of Helicobacter pylori was inhibited by the quinones, idebenone, duroquinone, menadione, juglone, and coenzyme Q 1 at low concentrations of 0.8 to 3.2 g/ml. Idebenone specifically inhibited H. pylori growth by inhibiting respiration and decreasing the cellular ATP level. The respiratory inhibition was accompanied by reduction of idebenone by the H. pylori cells.
measurement of the cellular ATP level in H. pylori with inhibitors were carried out as described previously (14) . As shown in Table 3 , idebenone inhibited cellular respiration with L-proline, L-serine, and L-alanine as well as pyruvate and succinate as respiratory substrates at 50% inhibitory concentration (IC 50 ) values of 2.0 to 3.5 g/ml, which were close to the MIC against H. pylori growth.
Since ATP production has been suggested to be coupled to respiration, as described previously for H. pylori (14) , we examined the dose response of idebenone with respect to the cellular ATP level when succinate was used as a respiratory substrate. We found that idebenone dose-dependently decreased the cellular ATP level, suggesting that it can inhibit ATP production coupled to respiration (data not shown).
We next considered whether L-proline dehydrogenase, which is essential for respiratory activity, might be target of idebenone. An assay based on the 2,6-dichlorophenolindophenol-reducing activity of L-proline, described previously (13) , showed that L-proline dehydrogenase was not inhibited by idebenone even at the concentration of 20 g/ml.
Idebenone in the oxidized state has an adsorption peak at 275 nm, and the peak decreases in the reduced form (17) . Assay of the reducing activity of idebenone by H. pylori cells showed that idebenone outside the cells was reduced time dependently when the cells were incubated with idebenone at (Fig. 1) . After 2 min, almost maximum reduction of idebenone was observed and the mode of the reduction was similar to that of the respiratory inhibition ( Fig. 1 ). Bacteria contain two main types of quinones, ubiquinone and menaquinone, which mediate electron transfer between dehydrogenase and reductase or oxidase components of respiratory chains (18) . Menaquinone is the major quinone in H. pylori (5, 9). Wang et al., based on work using quinones such as coenzyme Q 1 , menadione, and 1,4-naphthoquinone, reported that H. pylori has the activity of NADPH-specific quinone reductase (20) . In the present study, the cell-free homogenate obtained from sonicated H. pylori showed NADPH-idebenone reductase activity (data not shown). We found that idebenone, which easily crosses the cell membrane (3, 15) , is reduced time dependently by H. pylori cells (Fig. 1) . The hydrogen derived from various respiratory substrates may reduce idebenone inside the cells, which may, in turn, affect the component(s) in the respiratory chain of H. pylori.
Support for our hypothesis comes from the finding that the cellular respiration of microaerophilic C. jejuni, which has a similar energy metabolic pathway to that of H. pylori, was not inhibited by idebenone (data not shown). C. jejuni cells did not reduce idebenone, and the cell-free homogenate did not show the activity of NADPH-idebenone reductase (data not shown). Based on these observations, the action of idebenone against H. pylori growth is considered to be due to its inhibition of respiratory activity coupled to ATP production. Precise identification of the inhibitory target of idebenone in the respiratory chain of H. pylori will require further investigation using a cell-free system of H. pylori.
In contrast to the case for H. pylori observed in the present work, in human mitochondria, idebenone at 6.7 to 20 g/ml was found to dose dependently stimulate respiration using succinate (17) . Since idebenone seems to have no serious side effects in humans (3, 10, 15, 17) , our findings should be useful for developing new quinone analogs to eradicate H. pylori.
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